BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Uppal A, Rahman S, Campbell JR, Oxlade O, Menzies D. Economic and modeling evidence for tuberculosis preventive therapy among people living with HIV: A systematic review and meta-analysis. PLoS Med 2021;18:e1003712. [PMID: 34520463 DOI: 10.1371/journal.pmed.1003712] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Kota NT, Shrestha S, Kashkary A, Samina P, Zwerling A. The Global Expansion of LTBI Screening and Treatment Programs: Exploring Gaps in the Supporting Economic Evidence. Pathogens 2023;12:500. [PMID: 36986422 DOI: 10.3390/pathogens12030500] [Reference Citation Analysis]
2 Agbota G, Bonnet M, Lienhardt C. Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges. Pathogens 2023;12:362. [DOI: 10.3390/pathogens12030362] [Reference Citation Analysis]
3 Vo LNQ, Nguyen VN, Nguyen NTT, Dong TTT, Codlin A, Forse R, Truong HT, Nguyen HB, Dang HTM, Truong VV, Nguyen LH, Mac TH, Le PT, Tran KT, Ndunda N, Caws M, Creswell J. Optimising diagnosis and treatment of tuberculosis infection in community and primary care settings in two urban provinces of Viet Nam: a cohort study. BMJ Open 2023;13:e071537. [PMID: 36759036 DOI: 10.1136/bmjopen-2022-071537] [Reference Citation Analysis]
4 Vasiliu A, Abelman R, Kherabi Y, Iswari Saktiawati AM, Kay A. Landscape of TB Infection and Prevention among People Living with HIV. Pathogens 2022;11. [PMID: 36558886 DOI: 10.3390/pathogens11121552] [Reference Citation Analysis]
5 Blanc F. Virus de l’immunodéficience humaine et poumons : une association à problèmes. Revue des Maladies Respiratoires Actualités 2022;14:2S450-2S454. [DOI: 10.1016/s1877-1203(22)00779-0] [Reference Citation Analysis]
6 Zhu J, Lyatuu G, Sudfeld CR, Kiravu A, Sando D, Machumi L, Minde J, Chisonjela F, Cohen T, Menzies NA. Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. Lancet Glob Health 2022;10:e1646-54. [PMID: 36240830 DOI: 10.1016/S2214-109X(22)00372-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Vojnov L, Venter WDF. Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV. Lancet Glob Health 2022;10:e1549-50. [PMID: 36240815 DOI: 10.1016/S2214-109X(22)00408-9] [Reference Citation Analysis]
8 Kazibwe A, Oryokot B, Mugenyi L, Kagimu D, Oluka AI, Kato D, Ouma S, Tayebwakushaba E, Odoi C, Kakumba K, Opito R, Mafabi CG, Ochwo M, Nkabala R, Tusiimire W, Kateeba Tusiime A, Alinga SB, Miya Y, Etukoit MB, Biraro IA, Kirenga B. Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study. PLoS ONE 2022;17:e0266285. [DOI: 10.1371/journal.pone.0266285] [Reference Citation Analysis]
9 Jiang C, Jiang L, Shi L, Jiang S, Pallikonda Rajasekaran M. Improved Algorithm-Based Magnetic Resonance Images Combined with Computed Tomography in the Diagnosis of Acquired Immune Deficiency Syndrome Combined with Spinal Tuberculosis. Scientific Programming 2022;2022:1-7. [DOI: 10.1155/2022/7140673] [Reference Citation Analysis]